Literature DB >> 12351265

A neurosteroid anesthetic, alphaxalone, inhibits nicotinic acetylcholine receptors in cultured bovine adrenal chromaffin cells.

Munehiro Shiraishi1, Izumi Shibuya, Kouichiro Minami, Yasuhito Uezono, Takashi Okamoto, Nobuyuki Yanagihara, Susumu Ueno, Yoichi Ueta, Akio Shigematsu.   

Abstract

UNLABELLED: Several lines of evidence suggest that nicotinic acetylcholine receptors (nAChRs) are a target of general anesthetics. Alphaxalone (5alpha-pregnan-3alpha-ol-11, 20-dion) is a neurosteroid, which was used clinically for anesthesia, but its effects on the function of nAChRs have not been well investigated. We examined the effects of alphaxalone on nAChRs in cultured bovine adrenal chromaffin cells. We studied the effects of alphaxalone on nicotine-induced increases in the cytosolic Ca(2+) concentration ([Ca(2+)](i)) and on membrane currents using Ca(2+)-imaging and whole-cell patch-clamp techniques, respectively, in these cells. We also examined the effects of alphaxalone on gamma-aminobutyric acid A receptors in the same cells and compared them with the effects on nAChRs. Alphaxalone (0.1-100 micro M) inhibited nicotine-induced [Ca(2+)](i) increases in a concentration-dependent manner. Alphaxalone inhibited high K(+)-induced [Ca(2+)](i) increases, but the inhibition was observed only at 100 micro M. In voltage-clamp experiments using negative holding potentials, alphaxalone (0.1-100 micro M) itself induced inward currents, which were abolished by the gamma-aminobutyric acid A receptor antagonist picrotoxin. Alphaxalone also inhibited nicotine-induced inward currents, and the inhibition was unaffected by picrotoxin. We conclude that alphaxalone, at anesthetic concentrations, inhibits nAChRs in adrenal chromaffin cells. Alphaxalone may affect the sympathetic and other nervous systems via inhibition of nAChRs. IMPLICATIONS: Alphaxalone inhibits the function of nAChRs at clinically relevant concentrations in adrenal chromaffin cells. Thus, the present findings may provide some information for understanding the anesthetic mechanism of alphaxalone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12351265     DOI: 10.1097/00000539-200210000-00020

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

1.  Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors.

Authors:  Brandon M Stell; Stephen G Brickley; C Y Tang; Mark Farrant; Istvan Mody
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-17       Impact factor: 11.205

2.  Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration.

Authors:  Nicole Ducharme; William A Banks; John E Morley; Sandra M Robinson; Michael L Niehoff; Claudia Mattern; Susan A Farr
Journal:  Eur J Pharmacol       Date:  2010-06-08       Impact factor: 4.432

3.  Capsaicin inhibits catecholamine secretion and synthesis by blocking Na+ and Ca2+ influx through a vanilloid receptor-independent pathway in bovine adrenal medullary cells.

Authors:  Kojiro Takahashi; Yumiko Toyohira; Susumu Ueno; Masato Tsutsui; Nobuyuki Yanagihara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-07       Impact factor: 3.000

4.  The effects of the neurosteroids: pregnenolone, progesterone and dehydroepiandrosterone on muscarinic receptor-induced responses in Xenopus oocytes expressing M1 and M3 receptors.

Authors:  Takafumi Horishita; Kouichiro Minami; Yasuhito Uezono; Munehiro Shiraishi; Junichi Ogata; Takashi Okamoto; Tadanori Terada; Takeyoshi Sata
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-03-19       Impact factor: 3.000

5.  Dexmedetomidine inhibits muscarinic type 3 receptors expressed in Xenopus oocytes and muscarine-induced intracellular Ca2+ elevation in cultured rat dorsal root ganglia cells.

Authors:  Atsushi Takizuka; Kouichiro Minami; Yasuhito Uezono; Takafumi Horishita; Toru Yokoyama; Munehiro Shiraishi; Takeshi Sakurai; Akio Shigematsu; Yoichi Ueta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-06-12       Impact factor: 3.195

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.